OncLive | Targeting CD19 May Yield Paradigm-Altering Technology OncLive For the past two decades, researchers have been exploring B-cell specific antigens in hopes of developing a new anticancer target that would mirror the success of the CD20-targeting rituximab (Rituxan). Now, strategies aimed at CD19 are proving ... |
